Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension

Description

Yes / Aberrant transforming growth factor-β (TGF-β) signaling activation is linked to pulmonary arterial hypertension (PAH). BMPR2 mutations perturb the balance between bone morphogenetic protein (BMP) and TGF-β pathways, leading to vascular remodeling, narrowing of the lumen of pulmonary vasculature, and clinical symptoms. This forum highlights the association of the TGF-β pathway with pathogenesis and therapeutic approaches. / Research carried out at Nasim laboratories is funded by GrowMedtech, the Royal Society, the Commonwealth Scholarship Commission (CSC) and the University of Bradford (UoB). N.S. is funded by the CSC and C.C.N. is partly funded by the UoB.

Links & Downloads

1. Sharmin N, Nganwuchu CC and Nasim Md T (2021) Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension. Trends in Pharmacological Sciences. 42(7): 510-513.
2. http://hdl.handle.net/10454/18507
3. https://doi.org/10.1016/j.tips.2021.04.002

Tags

Pulmonary arterial hypertension

TGF-β

BMP

Pulmonary vasculature

ALK5 inhibitor

Additional Fields

Identifer	oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/18507
Date	23 May 2021
Creators	Sharmin, Nahid, Nganwuchu, Chinyere C., Nasim, Md. Talat
Source Sets	Bradford Scholars
Language	English
Detected Language	English
Type	Article, Accepted manuscript
Rights	© 2021 Elsevier Ltd. All rights reserved. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.